|
Real-time Estimate
Cboe Europe
20:20:00 02/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 14.96 CHF | -2.35% |
|
+5.20% | +18.89% |
| 10-23 | Santhera's Partner Seeks Marketing Permit in South Korea for Duchenne Muscular Dystrophy Treatment | MT |
| 10-23 | Nxera Pharma Files South Korean Marketing Application for DMD Drug | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Specialty & Advanced Pharmaceuticals | -2.22% | +5.20% | +18.89% | +45.44% | +12.63% | 285M |  | | |
- Stock Market
- Stocks
- SANN Stock
- Charts Santhera Pharmaceuticals Holding AG
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
